CHENGDU, China, Sept. 24 /PRNewswire-Asia-FirstCall/ -- -- Q4 FY 2009 Revenues increased 43.2% to $13.3 Million, Net Income increased 41.8% to $2.2 Million with diluted EPS of $0.08 -- FY 2009 Revenues increased 28.2% to $42.9 Million and Net Income Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS of $0.32 -- FY 2009 Cash flow from operations increased 124.8% to $8.3 Million -- June 30, 2009 Cash and equivalents of $12.4 million, working capital of $19.3 million and current ration of 5.4 to 1 -- Completed construction and received GMP approval for its new manufacturing facility -- Company successfully launched 9 products during FY09 -- Reaffirms Fiscal 2010 Guidance: Revenues Expected to Exceed $59 Million with a Net Income of at Least $10.5 million
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
Fourth Quarter Ending June 30, 2009 Financial Results
Fourth quarter 2009 revenues were $13.3 million, representing a 43.2%
increase from $9.3 million recorded in the fourth quarter of fiscal 2008. The
increase was driven by enhanced marketing and advertising programs supporting
a broader product portfolio and improvements in the Company's sales channels
which led to increased market penetration. Revenues in the fourth quarter
generated by the top three selling products, Ginkgo Mihuan Oral Liquid, Arpu
Shuangxin Oral Liquid, and Azithromycin Dispersible Tablets, were collectively
$7.8 million and represented approximately 58.6% of total revenues for the
quarter. During the fourth quarter of fiscal 20
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2009 PR Newswire.
All rights reserved